Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma

Gamel, John W.; McLean, Ian W.; McCurdy, Jeffrey D.

doi:10.1002/1097-0142(19930401)71:7<2299::aid-cncr2820710721>3.0.co;2-g

Cited by 76 publications

(56 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found very high expression of all four proteins studied in uveal melanoma lesions. Metastatic uveal melanoma tissue is hard to obtain, as the liver is the primary metastatic site of uveal melanoma and these metastases are discovered relatively late (Gamel et aL 1993). In the few metastases that we could include, we found a mi ed expression of gplOO and TRP-1 compared with the high expression of tyrosinase and MART-1.…”

Section: Discussionmentioning

confidence: 73%

“…Upon discovery of hepatic metastases, usually by fine-needle aspiration, the time of survival of a uveal melanoma patient is dramatically low, usually between 2 and 4 months (Gamel et al, 1993 Exression in pmary tours (A-E) and in rnetastases (F-J) iS Shon. Homogeneous sbong staiing for gpl00 with antbody NKI4beteb (A), TRP-1 (B), tyrosnae (C) and its negative contro (D) in the different primary tumos is displayed.…”

Section: Discussionmentioning

confidence: 99%

“…tyrosinase and TRP-1 in uxeal melanoma lesions. albeit that mRNA of three of these markers has been detected in uveal melanomas (Mulcahv et al 1996) (Gamel et al, 1993). The four metastases were from different patients and were excised from the parotid gland, lymph node, brain and skin.…”

mentioning

confidence: 99%

See 2 more Smart Citations

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma

Vries

Trancikova²,

Ruiter³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary In the treatment of cutaneous melanoma, provisional therapeutic strategies have been designed to combat tumour load using T cells that are sensitized with peptides derived from melanoma autoantigens, such as glycoprotein 100 (gp100), melanoma antigen recognized by T cells 1 (MART-1 or MelanA), tyrosinase and tyrosinase-related protein 1 (TRP-1). We recently found that gpl 00, MART-1 and tyrosinase are heterogeneously expressed in human cutaneous melanoma (De Vries et al (1997) Monoclonal antibodies against gplOO has-e successfullv been implemented in diagnostic pathology of cutaneous and uveal melanoma (Carrel and Rimoldi. 1993: Ruiter andBrocker. 1993).Antibodies against three other melanoma antigens. MART-I (Chen et al. 1996). tyrosinase (Chen et al. 1995) and TRP-1 (Chen et al.1995) have recentlx been described. The recent discoxerx that peptides derived from gplOO (Bakker et al. 1994 (Tobal et al. 1993: Foss et al. 1995.For both those who design immunotherapy protocols and those w ho perform RT-PCRs based on the presence of melanomaspecific mRNA in patients blood, it is important to knoxx the content of these antigens in primary tumours. Recentlv. we studied the presence of gp 100. MART-1 and tyrosinase in cutaneous melanocvtic lesions. We found that approximately 20% of the

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma

Vries

Trancikova²,

Ruiter³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The postbrachytherapy follow up included A-scan and B-scan ultrasonography and a clinical examination (including metastatic evaluation) 3 months after the surgery and every 6.6 (0.3) (mean (SE)) months thereafter (a total of 1001 examinations). Each patient was examined on average 5.6 times (range [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]. Thirty three of the 147 patients died during the…”

Section: Resultsmentioning

confidence: 99%

Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma

Kaiserman

Anteby²,

Chowers³

et al. 2004

British Journal of Ophthalmology

View full text Add to dashboard Cite

Aim: To confirm the prognostic value of post-brachytherapy initial tumour regression rate in posterior uveal melanoma. Methods: A prospective, comparative, observational cohort study was carried out on 147 eyes (147 patients) with choroidal melanoma (mean age 61 years) treated with Ru-106 brachytherapy. Observation procedure: Patients were followed clinically and ultrasonically every 6.7 (SD 0.3) months (1001 examinations). On average each patient was examined 5.8 times (mean follow up 9.6 (3.7) years). The echographic parameters included tumour base size, height, internal reflectivity, regularity, vascularity, and extrascleral extension. The clinical follow up included ocular examination and periodic metastatic screening (liver function tests and liver imaging). Main outcome measures were risk of liver metastasis in correlation with the post-brachytherapy initial tumour regression rate. Results: At brachytherapy the mean tumour height was 5.2 mm (range 2.2-11.8 mm). After brachytherapy 142 tumours (96.6%) responded by a decrease in height. The initial height regression rate was 6.1% (0.8%) per month in patients who later developed metastasis v 4.3% (0.4%) per month in those who did not. Tumours higher than 6 mm, tumours with an internal reflectivity smaller than 50%, and tumours with an initial rate of height regression larger than 0.7 mm/month (10% per month) had higher 5 year melanoma related mortality. Kaplan-Meier survival analysis and the multivariate Cox proportional hazards model showed a significant role for tumour height and initial tumour regression rate on patients' survival. Conclusion: This study confirms that post-brachytherapy initial tumour regression rate has a prognostic value.

show abstract

“…Approximately half of patients with uveal melanoma will experience metastasis within 10 years of diagnosis, irrespective of type of treatment received [12,[60][61][62][63][64]. The median survival after metastasis is 6-12 months; however, the median survival of patients receiving treatment is better than those not receiving treatment [59].…”

Section: Diagnosis and Prognosis Of Uveal Melanomamentioning

confidence: 99%

Uveal Melanoma: A Review of the Literature

2018

View full text Add to dashboard Cite

Melanomas affecting different components of the uvea occur with differing frequencies and clinical presentations. Uveal melanoma is diagnosed via funduscopic exam and ancillary tests. These lesions may present with visual findings or incidental findings on physical exam. Metastasis occurs in approximately half of all patients with primary uveal melanoma. The liver is the most common site of metastasis. Enucleation was at one time considered the definitive local treatment for primary uveal melanoma, but has been largely replaced by other therapeutic procedures that aim to prevent metastasis while preserving vision. Unfortunately, metastasis of uveal melanoma almost always proves to be fatal. The current treatment of metastatic uveal melanoma is limited by the intrinsic resistance of uveal melanoma to conventional systemic therapies. Advancements in molecular biology have resulted in the identification of a number of promising prognostic and therapeutic targets. Early detection and therapy are important factors in disease survival. It is imperative that the treating physician be familiar with the clinical features of uveal melanoma and distinguish it from mimickers in order to ensure effective and timely treatment.

show abstract

Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma

Cited by 76 publications

References 9 publications

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma

Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma

Uveal Melanoma: A Review of the Literature

Contact Info

Product

Resources

About